- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04183062
BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
A Phase 2 Study of the Safety and Efficacy of BIO-11006 in the Treatment of Recurrent Osteosarcoma and Ewing's Sarcoma in Patients With Lung Metastases
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33155
- Nicklaus Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologic verification of Ewing's sarcoma or osteosarcoma at original diagnosis or at relapse
- Recurrence within one year of end of previous therapy
- Presence of lung metastases
- Osteosarcoma patients must be ineligible for curative surgery
- Ability to take inhaled medication by nebulizer and be willing to adhere to the BIO-11006 regimen
- Females of reproductive potential must have a negative pregnancy test at screening and must agree to use a method of highly effective contraception during study participation.
- Males of reproductive potential must agree to the use of condoms or other methods to ensure effective contraception with partner
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Provision of signed and dated informed consent form
Exclusion Criteria:
- Previously treated and progressed on gemcitabine and docetaxel
- Central Nervous System (CNS) metastases
- Contraindication to gemcitabine or docetaxel
- Known allergic reactions to components of BIO-11006
- Use of medications that are primarily metabolized by cytochrome P450 isoenzymes
- Treatment with another investigational drug within 8 weeks of enrollment.
- Current pneumonia or idiopathic pulmonary fibrosis
- Absolute Neutrophil Count (ANC) < 750 cells/mm3
- Platelet count < 75,000 cells/mm3
- Hemoglobin <8.0 g/dL
- Creatinine clearance (CrCL) < 45 mL/min
- Bilirubin > upper limit of normal (ULN) for age
- AST and/or ALT >1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN
- Organ transplant or bone marrow transplant recipient
- Pregnancy or lactation
- Current smoker or tobacco use within 3 months prior to enrollment
- Any febrile illness or other severe illness within 2 weeks of enrollment
- Known history of human immunodeficiency virus, hepatitis B, hepatitis C or tuberculosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chemotherapy plus BIO-11006
Patients will receive BIO-11006 in addition to GemTax chemotherapy.
The BIO-11006 inhalation solution will be given by mouth inhalation twice daily.
BIO-11006 will be given during the first three cycles of GemTax and then will be stopped.
Subjects will continue with GemTax treatment for three additional cycles.
If the patient shows lung progression (either clinical or on imaging) at any point after cycle 4 has been given, but had shown at least a partial response during the tumor assessment after cycle 3, BIO-11006 may be re-started at the discretion of the investigator and continued for the duration of the GemTax treatment.
|
BIO-11006 will be administered at a dose of 75 mg twice daily for patients over 5 years of age and under 18 years of age or 125 mg twice daily for patients 18 years of age or older. The study drug will be administered twice daily by nebulizer over 20 minutes. GemTax will be administered in 21-day cycles. Gemcitabine will be administered at a dose of 900 mg/m2 IV over 90 minutes on days 1 and 8. Docetaxel will be administered at a dose of 75 mg/m2 IV over 60 minutes on day 8. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety - Treatment-emergent adverse events (TEAEs)
Time Frame: Up to 16 months
|
Frequency, type, severity, and duration of TEAEs.
Sources of TEAEs may include spontaneous patient reports, results of physical examinations, and clinical laboratory measurements.
Simple descriptive statistics of frequencies, centrality and variability will be utilized to tabulate and summarize TEAEs.
If sufficient number of TEAEs will be captured, frequencies, duration and severity will be compared.
|
Up to 16 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy - Progression Free Survival (PFS)
Time Frame: Up to 16 months
|
PFS will be measured from Cycle 1 Day 1 until occurrence of event (such as death, disease progression or end of study).
|
Up to 16 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Guillermo De Angulo, MD, Nicklaus Children's Hospital
Publications and helpful links
General Publications
- Blackshear PJ. The MARCKS family of cellular protein kinase C substrates. J Biol Chem. 1993 Jan 25;268(3):1501-4. No abstract available.
- Brown HK, Schiavone K, Gouin F, Heymann MF, Heymann D. Biology of Bone Sarcomas and New Therapeutic Developments. Calcif Tissue Int. 2018 Feb;102(2):174-195. doi: 10.1007/s00223-017-0372-2. Epub 2017 Dec 13.
- Green TD, Park J, Yin Q, Fang S, Crews AL, Jones SL, Adler KB. Directed migration of mouse macrophages in vitro involves myristoylated alanine-rich C-kinase substrate (MARCKS) protein. J Leukoc Biol. 2012 Sep;92(3):633-9. doi: 10.1189/jlb.1211604. Epub 2012 May 23.
- Grohar PJ, Janeway KA, Mase LD, Schiffman JD. Advances in the Treatment of Pediatric Bone Sarcomas. Am Soc Clin Oncol Educ Book. 2017;37:725-735. doi: 10.1200/EDBK_175378.
- Hartwig JH, Thelen M, Rosen A, Janmey PA, Nairn AC, Aderem A. MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-calmodulin. Nature. 1992 Apr 16;356(6370):618-22. doi: 10.1038/356618a0.
- Singer M, Martin LD, Vargaftig BB, Park J, Gruber AD, Li Y, Adler KB. A MARCKS-related peptide blocks mucus hypersecretion in a mouse model of asthma. Nat Med. 2004 Feb;10(2):193-6. doi: 10.1038/nm983. Epub 2004 Jan 11.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplastic Processes
- Neoplasms, Bone Tissue
- Neoplasms, Connective Tissue
- Sarcoma
- Neoplasm Metastasis
- Sarcoma, Ewing
- Osteosarcoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Gemcitabine
- Docetaxel
Other Study ID Numbers
- 2019023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteosarcoma Metastatic
-
Children's Oncology GroupNational Cancer Institute (NCI)Not yet recruitingMetastatic Osteosarcoma | Localized Osteosarcoma | Unresectable Osteosarcoma | Resectable Osteosarcoma
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Ewing Sarcoma | Recurrent Osteosarcoma | Stage III Osteosarcoma AJCC v7 | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma | Metastatic Ewing Sarcoma | Unresectable Ewing Sarcoma | Unresectable OsteosarcomaFrance
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized Osteosarcoma | Osteoblastic OsteosarcomaUnited States
-
National Cancer Institute (NCI)SuspendedMetastatic Osteosarcoma | Localized Osteosarcoma | High Grade Osteosarcoma | Secondary OsteosarcomaUnited States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Unresectable Osteosarcoma | Locally Advanced OsteosarcomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized OsteosarcomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Metastatic Angiosarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Recurrent Angiosarcoma | Refractory Dedifferentiated LiposarcomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized OsteosarcomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Refractory Osteosarcoma | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic OsteosarcomaUnited States, Canada, Puerto Rico
-
Children's Oncology GroupNational Cancer Institute (NCI); University College, London; Medical Research...CompletedMetastatic Osteosarcoma | Localized OsteosarcomaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Clinical Trials on Chemotherapy (gemcitabine & docetaxel) plus BIO-11006
-
BioMarck Pharmaceuticals, Ltd.CompletedNon Small Cell Lung Cancer Stage IIIBIndia
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina
-
Samsung Medical CenterUnknownNon-small Cell Lung Cancer MetastaticKorea, Republic of
-
Samsung Medical CenterActive, not recruitingSalivary Gland CancerKorea, Republic of
-
Samsung Medical CenterSanofiCompletedCarcinoma, Non-Small-Cell LungKorea, Republic of
-
Clinical Hospital Centre ZagrebActive, not recruitingNon-muscle-invasive Bladder CancerCroatia
-
Sun Yat-sen UniversityUnknownNasopharyngeal NeoplasmsChina
-
Shanghai Jiao Tong University School of MedicineShanghai 10th People's Hospital; Jiangxi Provincial Cancer Hospital; Shanghai... and other collaboratorsRecruitingRecurrent Non-small Cell Lung CancerChina
-
AstraZenecaRecruitingBiliary Tract CancerFrance, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore